At last! A patient-centred statement on the proposed EU Clinical Trials Regulation

First, a brief history of time in the Europe Union (EU). It goes slowly. That's it! For the last two years or so the European Commission has been consulting on plans to revise the European Clinical Trials Directive.  The Directive has been in force since 2001.  Researchers hate it.  To be fair so do many … Continue reading At last! A patient-centred statement on the proposed EU Clinical Trials Regulation

Y’All: I still don’t really know what the BIS Science and Society strategy is about, do you?

I've been meaning to post this ever since it came across my Twitter feed some weeks ago. If you go on the Department for Business, Innovation and Skills (BIS) Science and Society Strategy pages you'll see that they have published updated action plans for each of the 'Expert Groups' set up in 2010.  These groups were tasked to … Continue reading Y’All: I still don’t really know what the BIS Science and Society strategy is about, do you?

Patient View launches EU health ‘apps’ directory

Patient View have today launched a new EU director of health 'apps' - these are the things people download onto iPhones and other smartphone devices.   As I understand it each of the health 'apps' was recommended by patient groups and patients across the European Union. They are categorised according to the service they provide.  You … Continue reading Patient View launches EU health ‘apps’ directory

There is no point to the javelin

It has come to this.  The world's top tennis players rush their shots to beat an 11pm curfew.  Bruce and Sir Paul are turned-off mid-performance.  And they don't use real javelins in schools. Looking across the the athletics field at my sons' school sports day, I spied a clutch of children competing in the javelin.  Except this … Continue reading There is no point to the javelin

Regulators push openness agenda on raw trial data…and EUPATI issues call for examples of educational materials on medicines development

Yes, that is a long headline is it not?  PharmaTimes and others cover a paper in PloS Medicine authored by a number of medicines regulators including the European Medicines Agency (EMA), calling for openness in raw trial data. The three pronged approach they suggest looks like a good basis for discussion.  It would be interesting … Continue reading Regulators push openness agenda on raw trial data…and EUPATI issues call for examples of educational materials on medicines development

EU initiative to boost information for patients on medicines development

The EU economy might be splintering apart.  But, meanwhile, a number of patient/public/private organisations are 'euro-zoning' in on the task of providing better information for patients on medicines development. The new initiative - which was launched on 1st February - is called the European Patients Academy on Therapeutic Innovation  or EUPATI for short. Thank goodness they did … Continue reading EU initiative to boost information for patients on medicines development

Ill-informed consent: EU meeting lays into clinical trials small print for patients

Image by erjkprunczyk via FlickrDaniel Cressey at Nature has written this report from last week's meeting of the European Forum for Good Clinical Practice which took place in Brussels. The basic thrust of the discussion at the meeting was that information given to patients prior to them signing up for a clinical trial: is often vague, too long, … Continue reading Ill-informed consent: EU meeting lays into clinical trials small print for patients